Infantile nystagmus syndrome (INS) is a group of disorders presenting with genetic and clinical heterogeneities that have challenged the genetic and clinical diagnoses of INS. Precise molecular diagnosis in early infancy may result in more accurate genetic counseling and improved patient management.
I nfantile nystagmus syndrome (INS) is a heterogeneous disorder characterized by continuous oscillation of the eyes with variable visual acuity. Infantile nystagmus syndrome is an important clinical diagnosis because nystagmus is a common presenting sign of many ocular, neurologic, and systemic diseases. 1 Nystagmus can be associated with low vision in early infancy owing to several causes, such as Leber congenital amaurosis (LCA), PAX6 (OMIM 607108)-related phenotypes, or albinism, which makes the differential diagnosis of INS more complex. Furthermore, ophthalmologists can miss subtle retinal abnormalities because continually oscillating eyes hinder the performance of detailed clinical examination. Therefore, meticulous clinical workups using optical coherence tomography (OCT), visual evoked potential, and electroretinography (ERG), are important to differentiate underlying causes of nystagmus. However, results of electrophysiological testing are often inconclusive in pediatric patients. In addition, young children often have been deemed unsuitable for conventional tabletop OCT.
Determining the precise genetic cause of INS has significant clinical relevance in terms of defining a firm molecular diagnosis and clarifying inheritance patterns, thereby guiding genetic counseling and precision medicine. Conventional Sanger sequencing of FRMD7 (OMIM 300628) and GPR143 (OMIM 300808) genes has been shown to be helpful for genetic diagnosis in familial INS, but no putative mutations have been identified in sporadic cases through Sanger sequencing of FRMD7 and GPR143, to our knowledge. 2 To date, more than 100 genes have been associated with INS, making it an ideal target for clinical application of next-generation sequencing (NGS). The aim of this study was to assess the clinical utility of NGS in the diagnosis of INS and to determine the clinical relevance of early molecular diagnosis in these patients.
Methods

Recruitment and Selection of Patients With INS
The cohort for this study included 48 consecutive patients of a single ethnicity (Korean) with infantile-onset (within 6 months of birth) nystagmus with or without associated ocular or systemic conditions who were willing to agree to undergo genetic testing between June 1, 2015, and January 31, 2017. All patients underwent ophthalmologic examinations, which included slitlamp examination if feasible, determination of the presence and type of nystagmus, fundus examination, and measurement of visual acuity. Electroretinography (Reti-port, Roland Consult, or RetEval, LKC Technologies) was performed according to International Society for Clinical Electrophysiology of Vision standards. 3 The ERG used skin electrodes in children younger than 6 years, and sedation with oral chloral hydrate was used in patients younger than 2 years. Spectral domain OCT (Heidelberg Engineering) was performed if applicable. A previous study described the OCT acquisition and analysis protocol in patients with nystagmus. 4 Eye movement recordings were performed with electro-oculography (Nicolet Compact Four/CA2000, Nicolet). Informed written consent was provided by patients and/or parents and peripheral blood samples were obtained for genetic analysis from all patients. This study was approved by Severance Hospital Institutional Review Board and adhered to the tenets of the Declaration of Helsinki. 5 
Targeted Gene Sequencing Using NGS Panel
For the customized NGS panel, we selected 113 candidate causative genes known to cause INS based on literature reviews, the RetNet database (available at https://sph.uth.edu/Retnet/), 6 and the Online Mendelian Inheritance in Man (OMIM) database (https://www.ncbi.nlm.nih.gov/omim) (eTable 1 in the Supplement). The TruSight One sequencing panel, which included 4813 genes associated with known clinical phenotype, was used in 1 patient (P15) owing to multiple systemic features.
Target enrichment was performed with molecular inversion probe-based capture method using a customized target enrichment kit (Celemics). Pooled libraries were sequenced using a MiSeq sequencer (Illumina) and the MiSeq Reagent Kit, version 2 (300 cycles).
NGS Data Analysis
Data analysis was performed primarily through our custom bioinformatic workflow. Briefly, raw sequence data were mapped to GRCh37 (hg19) using the Burrows-Wheeler Aligner algorithm, 7 followed by removal of duplicate reads, realignment of insertions and deletions, base quality recalibration, and variant calling using the Genome Analysis Toolkit. 8 Every variant that was suspected to be pathogenic, likely pathogenic, or a variant of unknown significance was confirmed by visual inspection of the BAM file using Integrated Genomics Viewer, version 2.3 (Broad Institute). Quality metrics were calculated for each sample using the FastQC software and Target Enrichment Quality Control package (eTable 2 in the Supplement). On average, more than 8.4 million reads were sequenced per sample, and approximately 8.3 million reads (97.7%) were mapped on references using the customized panel. The mean horizontal coverage, which was interpreted as percentage of regions with more than 30 × coverage, was 99.7%. Split-read-based detection of large insertions and deletions was conducted using the Pindel 9 and Manta algorithms, 10 and both results were finally crosschecked. Read-depthbased detection of structural rearrangements was conducted
Key Points
Question What is the diagnostic rate of targeted next-generation sequencing for infantile nystagmus syndrome?
Findings In this case series of 48 consecutive patients with infantile nystagmus syndrome, the diagnostic yield of targeted next-generation sequencing was 58.3%. The initial clinical diagnosis was revised in 10 of 48 patients after targeted next-generation sequencing.
Meaning Findings from this case series suggest that early application of targeted next-generation sequencing can be a front-line diagnostic tool to differentiate causes of infantile nystagmus syndrome.
using the ExomeDepth software. 11 Chromosomal copy number variations detected by ExomeDepth were further crosschecked using our custom bioinformatic workflow; this crosscheck retrieved base-level depth of coverage for each BAM file using SAMtools software 12 and normalized the depths against those of other samples in the same batch. We performed offtarget analysis of chromosomal copy number alterations using the CopywriteR software.
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Variant Filtering and Classification
The following databases were used for variant annotation: OMIM, Human Gene Mutation Database, ClinVar, dbSNP, 1000 Genomes, Exome Aggregation Consortium, Exome Sequencing Project, and Korean Reference Genome Database. The pathogenicity of missense variants was predicted using 5 in silico prediction algorithms, including SIFT (Sorting Intolerant From Tolerant), PolyPhen2, MutationTaster, MutationAssessor, and Functional Analysis through Hidden Markov Models implemented in dbNSFP version 3.0a. 14 Splice site analysis was determined using the MaxEntScan, NNSPLICE (Neural Network Splice Prediction), Human Splice Finder, GeneSplicer, and SpliceFinder-like algorithms implemented in the Alamut Visual software (Interactive Biosoftware). 15 The interpretation of variants followed the 5-tier classification system recommended by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology using a step-by-step approach (eFigure 1 in the Supplement). 16 The systematic approaches for variant classification are also described in the eAppendix in the Supplement. For the purpose of this study, patients were grouped in the following 3 categories: (1) probable molecular diagnosis: patients with pathogenic or likely pathogenic diseaseassociated variant(s); (2) possible molecular diagnosis: patients with 2 heterozygous mutations without segregation analysis, or patients harboring a single pathogenic or likely pathogenic disease-associated variant in a gene linked with recessive traits, provided the patient phenotype matches the known spectrum of clinical features for this gene; or (3) unsolved: all other patients for whom no pathogenic or likely pathogenic disease-associated variants were detected.
Confirmation Using Other Methods
For small nucleotide variations, pathogenic and likely pathogenic variants as well as variants of uncertain significance needing data from parents were examined using Sanger sequencing on a 3730 DNA Analyzer with the BigDye Terminator version 3.1 Cycle Sequencing kit (Applied Biosystems). Large exonic deletions and duplications were confirmed using the available multiplex ligation-dependent probe amplification kit (MRC-Holland). As a result, all variants from NGS presented in this study were further confirmed by Sanger sequencing or multiplex ligation-dependent probe amplification.
Results
This study included 48 patients (27 males and 21 females) with INS. None of the probands were of consanguineous parentage, and family history of nystagmus was noted in 8 of the 48 patients (17%). Six patients were consistent with an X-linked (Figure 2) . Representative cases are shown in Figure 3 , which depicts phenotypical similarities in 4 patients who all had different mutations. These patients were diagnosed with idiopathic infantile nystagmus at the initial visit. Four patients (8%) had single causative variants in a gene associated with recessive traits. Of the remainder (12 of 48 [25%]), we were unable to designate variants responsible for the compatible phenotypes (eTable 5 in the Supplement). Among 8 patients with familial INS, pathogenic or likely pathogenic variants were identified in 7 patients (88%). In the 40 patients with simplex, probable diagnosis was made in 21 patients, for a the diagnostic yield of targeted NGS of 53% (95% CI, 37.0%-68.0%).
Phenotypes According to Affected Genes With Pathogenic or Likely Pathogenic Mutations
All patients with LCA had compatible clinical phenotypes according to causative mutations. The most frequently mutated gene was GUCY2D (OMIM 600179) (n = 5), followed by PAX6 (n = 4). Two patients (P10 and P30) with RPGRIP1 (OMIM 605446) mutations were misdiagnosed with an idiopathic form of nystagmus at the initial visit. Compound heterozygous mutations of RPGRIP1 were identified in P30 (c.2079C>G, p.Tyr693Ter and c.2209_2215 + 18del) and P9 (c.2302C>T, p.Arg768Ter and c.3565_3571del, p.A rg1189GlyfsTer7), while a homozygous mutation of RPGRIP1 was found in P10 (c.3565_3571del). All 3 patients had horizontal jerk nystagmus and normal fundus appearance at the initial visit. One patient (P9) exhibited pigmentary retinopathy at the periphery and diffuse loss of ellipsoid zone on OCT findings at a subsequent visit (eFigure 4 in the Supplement). Another patient (P13) with CRB1 (OMIM 604210) mutations (c.1208C>G, p.Ser403Ter and c.1576C>T, p.Arg526Ter) first visited our clinic owing to horizontal nystagmus at 1 year of age. This patient's fundus was normal at the initial visit. At the subsequent visit, results of a dilated fundus examination revealed pigmentary retinopathy and thickened retina with degeneration of photoreceptor layers (eFigure 5 in the Supplement). One patient (P15) visited our clinic owing to horizontal nystagmus at 1 year of age. She had high hyperopia and a presumptive diagnosis of LCA was made. At 2 years of age, this patient developed acute renal failure and required kidney transplantation. Nextgeneration sequencing analysis revealed a homozygous c.3533G>A (p.Arg1178Glu) WDR19 (OMIM 608151) mutation. The clinical diagnosis was revised to Senior-Loken syndrome (eFigure 6 in the Supplement).
eFigure 7 in the Supplement shows the genotypes and clinical phenotypes in 4 patients with GPR143 mutations. All 4 patients exhibited absence of foveal reflex and grade 4 foveal hypoplasia detected by OCT. None exhibited an iris transillumination defect. In P17, pigmentation of the retina was normal, and he was initially diagnosed with idiopathic infantile nystagmus. At 14 years of age, OCT findings demonstrated grade 4 foveal hypoplasia. Next-generation sequencing revealed a noncanonical splice site c.659-3C>G GPR143 mutation. The normal 3′ splice site had broken and a new splice acceptor site was introduced at the c.659-3C>G position (eFigure 8intheSupplement).
Four patients with PAX6 mutations had grade 1-3 foveal hypoplasia according to the type of mutation. Fundus photographs revealed retained foveal reflex in 3 patients (eFigure 9 in the Supplement). One patient (P20) exhibited presenile posterior subcapsular cataract, and another (P21) underwent cataract surgery at 24 years of age. Except for P22, 3 patients had normal iris structures. One patient (P23) had only isolated foveal hypoplasia.
A hemizygous frameshift (c.342delC, p.Phe115SerfsTer22) mutation in CACNA1F (OMIM 300110) was identified in P28. This patient visited our clinic owing to horizontal nystagmus at 1 year of age. The fundus was normal except for a large cupdisc ratio, and findings of ERG testing were ambiguous at that time. This patient was initially thought to have idiopathic infantile nystagmus. At 5 years of age, ERG findings revealed the characteristic negative waveform in dark-adapted 3.0 ERG and double peak sign in light-adapted 30-Hz flicker, consistent with incomplete congenital stationary night blindness (eFigure 10 in the Supplement).
Mutation Hotspots in Koreans With INS
A total of 6 mutations in 4 genes (GUCY2D c.2649delT, c.3038G>A; NMNAT1 (OMIM 608700) c.196C>T, c.709C>T; CNGA3 (OMIM 600053) c.1001C>T; and RPGRIP1 c.3565_3571del) were detected in more than 2 unrelated patients in this study. Two variants in GUCY2D have not been described in any previous reports or reputable database, to our knowledge, nor were they detected in a normal population da-tabase. Because the 3 patients with these variants in GUCY2D were not related, these mutations may be candidate variants for founder mutation evaluation in the Korean population, fulfilling the criteria for segregation quantification for pathogenicity according to the recently refined guideline known as Sherloc. 
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Discussion
In this study, we analyzed 48 patients with INS to determine an effective strategy for making a firm molecular diagnosis of this disorder. Probable molecular diagnosis was made in 28 patients, corresponding to a diagnostic yield of 58.3%. Moreover, the results of genetic diagnoses enabled revision of initial clinical diagnoses, which eventually led to improvement of personalized care and genetic counseling. A previous study that evaluated the clinical utility of NGS in familial infantile nystagmus reported a detection rate of 80% (12 of 15 patients).
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This finding was consistent with our results in familial cases (7 of 8 patients [88% detection rate]). We found that none of the female obligate carriers of the GPR143 mutation had nystagmus. A previous study also reported that all obligate carriers with the GPR143 mutation exhibited no sign of nystagmus.
27,35 Female carriers with the GPR143 mutation exhibit only a mottled pattern of retinal pigmentation. 36 A female with FRMD7 mutation (P26) was affected in our study, and it has been reported that the penetrance of the FRMD7 mutation is 53% in female obligate carriers. 37 Ocular albinism can be misdiagnosed as idiopathic because hypopigmentation of the fundus and iris transillumination defects are relatively rare in Asian patients. 27 ,35 Therefore, NGS will facilitate genetic counseling and future family planning in X-linked familial INS. Most patients with LCA exhibit severe visual impairment in early childhood, which is accompanied by characteristic features such as roving eye movement, oculodigital sign, or amaurotic pupil. Unfortunately, pupillary response is difficult to evaluate in infants because of their small resting size. 38 In addition, patients with LCA may have fundi that appear normal during infancy.
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Moreover, patients with LCA with CEP290 (OMIM 610142) mutations have a wide spectrum of visual acuity abnormalities from light perception to greater than 0.5. 40 Therefore, early NGS testing will aid in differentiating LCA from other nonprogressive diseases with nystagmus such as achromatopsia. Nystagmus waveform may provide a clue to the sensory causes of nystagmus, 41 and handheld OCT will help clinicians locate retinal structural abnormalities. 42 A highfrequency, low-amplitude nystagmus, which is regarded as a characteristic waveform of sensory origin, may not be evident early in these patients. 38 In addition, obtaining the fovea center using OCT is difficult, especially in young children with nystagmus, and the interpretation of OCT findings can be misleading owing to poorly centered fovea imaging. Pediatric electrophysiology testing and handheld OCT are laborintensive endeavors conducted in a limited number of specialized facilities. Electrophysiology testing under sedation carries a risk for adverse events such as respiratory depression or ventricular arrhythmia. 43 Therefore, NGS has potential value in avoiding unnecessary ERG testing if NGS testing reveals FRMD7 or GPR143 mutations, and the inheritance is consistent with an X-linked recessive pattern. If causative mutations associated with retinal disorders are found, imaging or ERG testing will be needed to correlate genotypes and phenotypes.
Many studies have confirmed the clinical utility of NGS genetic testing in ophthalmic diseases. [44] [45] [46] Should targeted NGS be considered when a clinical context supports a specific diagnosis such as aniridia syndrome or ocular albinism? In these circumstances, NGS techniques may be more cost-effective than Sanger sequencing if the responsible gene has many exons. Next-generation sequencing can also detect copy number variations or variants in cis-regulatory regions of PAX6, known to cause phenotypes. The significant potential advantage of massive parallel sequencing in INS should be emphasized, as illustrated in patients with syndromic ciliopathic findings. Next-generation sequencing can enable physicians to increase surveillance for treatable manifestations of the disease if the correct diagnosis is made in a timely fashion. 47 In addition, decisions regarding brain neuroimaging can be tailored to individual patients with LCA through NGS testing. Targeted NGS is relatively focused and inexpensive, and can reveal deep intronic regions known to cause disease if particular deep intronic regions were included in the panel. Meanwhile, whole-exome sequencing has several strengths in that it does not require any gene list update, and data from new regions can be reanalyzed at a later time to discover novel causative genes. Whole-genome sequencing has the advantages of better detection of copy number variants and screening more broadly. However, the interpretation of variants in noncoding regions are limited; therefore, the clinical use of whole-genome sequencing for clinical molecular diagnosis is not yet warranted.
Limitations
Because CACNA1F, PAX6, and SLC38A8 (OMIM 615585) mutations also cause nystagmus without overt retinal dystrophy, 48 
Conclusions
This study demonstrated that NGS has a potential role in early diagnosis of both familial and sporadic cases involving INS. It also demonstrated that NGS is a useful tool for making accurate diagnoses, which in turn have made revision of initial clinical diagnoses possible. Early molecular diagnosis of INS will enable physicians to conduct genetic counseling for further family planning and personalized care in a timely fashion.
Given the high prevalence of nystagmus in various causes of ocular and systemic diseases and the phenotypical similarities of nystagmus, greater attention should be devoted to making a clinical diagnosis in these patients. The discovery of ocular disease genes and the development of rapid next-generation genetic sequencing have created new opportunities for genetic diagnostic testing for inherited eye disorders. Next-generation sequencing (NGS) has also been termed massive parallel sequencing because the technology sequences fragments of DNA many times before aligning the sequence to a reference genome. The advantages over traditional Sanger sequencing are improved accuracy and increased capacity, which allow for rapid and precise large-scale sequencing. Next-generation sequencing technologies can be used to sequence entire genomes, exomes (all the proteincoding sequences in a genome), or panels of genes known to cause a selected disease. Several panel tests are already in clinical use for genes known to cause retinal dystrophies, earlyonset glaucoma, and inherited optic neuropathies.
1,2 Gene panel tests are particularly useful for genetically heterogeneous conditions, such as inherited retinal degenerations. In a study by Rim et al 3 in this issue of JAMA Ophthalmology, NGS was used to sequence a panel of genes known to underlie the development of nystagmus early in life, a clinical diagnosis that can accompany a diverse array of disorders. When successful, genetic testing can inform genetic counseling, identify associated health risks, and provide the molecular diagnoses necessary for the initiation of gene therapies. The usefulness of a genetic test depends on clinical sensitivity (diagnostic yield), the sensitivity and specificity of sequence detection, accuracy, and repeatability.
2 Sequencebased tests are very sensitive, specific, and accurate and have high repeatability measures, 2 and testing for ocular disorders can have excellent clinical sensitivity, with the ability to identify a diagnosis (diagnostic yields) ranging from 76% for inherited retinal degenerations to 25% for childhood glaucoma. 4, 5 A strength of the study by Rim et al 3 is the diagnostic yield of nearly 60%, a relatively high figure, for the patients with infantile nystagmus enrolled in their study. The study also identified mutations causing disorders with various inheritance pat- First (step 1), variants were filtered by their frequencies in population control databases, including Exome Aggregation Consortium (non-TCGA dataset; frequencies were calculated according to ethnic subgroups), ESP6500, 1000 Genomes Project, and Korean Reference Genome DataBase. To maximize the diagnostic yield, variants with a minor allele frequency greater than 5% in any of the population subgroups rather than conventional 1% criteria were classified as absolutely benign, whereas those that were absent from the general population were considered to have moderate evidence as pathogenic. Secondly (step 2), literature and database searches for previous reports and functional studies were performed using the RetNet database, the Alamut Visual software and Human Gene Mutation Database professional database. Pathogenic or benign evidence was scored when predictions of all in silico algorithms agreed. Finally, the last step involved genetic specialists or laboratory physicians presenting a preliminary report to the patient's attending physicians or pediatric ophthalmologists, which listed all possible pathogenic variants, likely pathogenic variants, and variants of unknown significance (VUSs). When pathogenic or likely pathogenic variants were consistent with the patient's phenotype based on in-depth review by ophthalmologists, final validation using other confirmatory assays and a parental study was planned if available. VUSs, especially missense variants, were prioritized according to population frequency, American College of Medical Genetics score, and the patient's ocular phenotype. A parental study was scheduled to detect de novo occurrence for the candidate pathogenic or likely pathogenic variants, and VUSs in all available trios.
Systematic approaches for variant classification
Variant classification followed a three-step approach. First, conventional bioinformatics analysis found 16 variants in 15 patients that were classified as likely pathogenic based on the nature of the mutation (mostly null variants) and frequencies in the normal populations. No variant could be classified as definitely pathogenic during the first step. In the second step, extensive literature reviews and database searches were conducted for the variant and other variants in the same amino acid position. When combined with in silico analysis, 13 additional variants could be classified as likely pathogenic mutations and 5 variants previously classified as likely pathogenic after the first step were re-classified as pathogenic mutations during the second step. Diagnostic yield, which was calculated as the proportion of solved patients with sufficient pathogenic or likely pathogenic mutations among the 48 patients, increased from 14.9% to 25.5% during the second step. The third step included genotype-phenotype correlations, consensus discussion among geneticists and clinicians, family study and segregation results, and additional confirmatory assays. Finally, 24 variants could be identified as likely pathogenic and 19 variants identified as pathogenic in a total of 32 patients. The final diagnostic yield reached 66.7%.
